

BIOTECHNOLOGY AND BIOSIMILAR LANDSCAPE IN TURKEY



Aysen Senturk

19.06.2017

Rome



Objectives & Methods



Background

- In recent years with the development of the technology, the importance of biotechnological drugs has been increasing
- Biosimilar drugs- are alternatives to biotechnologic drugs and the pricing and reimbursement policies of these drugs are being discussed by decision makers. These drugs play significant role in the Turkish pharmaceutical market.

Objective


- The purpose of this study is to analyze the regulations and the policies of biotech and biosimilar drug markets and to identify its market share in pharmaceutical industry.

Methods


- The study was undertaken from the Turkish health care payer perspective.
- An excel sheet was formed to calculate the results. Resource data were obtained from literature review.

Results

Licensed Biotechnology & Biosimilar Drugs in Turkey



THE FIRST FIVE COUNTRIES THAT BIOTECH DRUGS ARE IMPORTED



Turkish Pharma Market	TRY	€ (3,94 FX)	Market Share
Pharma Market	20.67 billion TRY	5 billion €	%100
Biotechnology Market	3.4 billion TRY	862 million €	%16,4
Biosimilar Market	126,76 million TRY	32 million €	%1



Conclusion & Summary



The first biosimilar drug was licensed in 2009 and the first biosimilar drug to be manufactured locally was licensed in oncology therapeutic area in 2016.

All biotech and biosimilar drugs are subject to the reference pricing system, locally manufactured biosimilars can have a 15% premium price with a cost card. They are classified as original products and reimbursed with %41 public discount.

Biosimilar Draft Guideline is prepared by MoH but it has not been published officially yet. Pricing of biosimilar products are also being contemplated to be referenced up to 100% of the original product in the Pricing Notification, which is still under consideration

There is not a differentiated pricing and reimbursement procedure or HTA procedure for biotech and biosimilar drugs than for the original drugs in Turkey but this application is being considered. Moreover, prioritization and localization incentives are on the agenda of the decision makers.

Thank You...

